STOCK TITAN

Lexeo Therapeutics (LXEO) Stock News, Dec 2023-May 2024

LXEO NASDAQ

Lexeo Therapeutics, Inc. develops clinical-stage genetic medicines for cardiovascular diseases, with company updates centered on AAV-based gene therapy candidates and related cardiac delivery technology. Its portfolio includes LX2006 for Friedreich ataxia cardiomyopathy and LX2020 for PKP2-associated arrhythmogenic cardiomyopathy.

Recurring developments include clinical data from cardiac gene therapy studies, FDA and CMC engagement, manufacturing work involving an optimized Sf9-baculovirus AAV platform, research collaborations for targeted cardiac delivery, quarterly financial results, conference presentations, and leadership or board changes tied to the company’s cardiovascular medicine focus.

Rhea-AI Summary

Lexeo Therapeutics, Inc. (Nasdaq: LXEO) will participate in upcoming investor conferences to discuss their innovative treatments for cardiovascular diseases and Alzheimer's disease. The company's management will engage in fireside chats at various events, providing investors with valuable insights into their genetic medicine advancements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.06%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.43%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.23%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.23%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.94%
Tags

FAQ

What is the current stock price of Lexeo Therapeutics (LXEO)?

Lexeo Therapeutics (LXEO) last closed at $2.95.

What is the market cap of Lexeo Therapeutics (LXEO)?

The market cap of Lexeo Therapeutics (LXEO) is approximately $244.2M.